Zydus Lifesciences gets USFDA nod for generic ascorbic acid injection

Zydus Lifesciences secured final USFDA approval for its generic ascorbic acid injection. This approval is for the treatment of scurvy in specific patient groups. The company's product is the generic equivalent of the Ascor injection. The USFDA designated this application as a Competitive Generic Therapy. Zydus will market the product in the United States market.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/m7sBK6b
via IFTTT

Read More

Medical devices industry needs to focus more on local value addition: Pharma Secy

The medical devices sector must increase local value addition and component manufacturing. Government officials are open to industry suggestions for PLI scheme beneficiaries. Many companies invested but could not claim incentives for various reasons. The government aims to incentivize component makers more than assembly operations. Increased domestic value addition is a key objective for the sector.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/O5IK8kP
via IFTTT

Read More

Delhi High Court rules in favour of Dr Reddy's Labs in trademark row with Razenta

The Delhi High Court ordered the removal of Razenta Pharmaceuticals' Daplogin trademark. This decision came as the mark was deemed deceptively similar to Dr Reddy's Labs' Daplo trademark. Both trademarks are used for prescription drugs treating Type-2 diabetes Mellitus. The court cited phonetic similarity and potential consumer confusion as key reasons. Razenta's trademark registration was cancelled within six weeks by the court.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/bBO9zsi
via IFTTT

Read More

Lupin arm to commercialise YUVEZZI eye drop across key European markets

Lupin's VISUfarma BV has secured exclusive rights for YUVEZZI in key European markets. This ophthalmic product treats loss of clear close-up vision in adults. VISUfarma will undertake regulatory activities and commercialization of the eye drop. The agreement includes a strategic investment and potential milestone payments. YUVEZZI represents a significant advancement in eye care for presbyopia.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/bm03Nq4
via IFTTT

Read More

Moderna, Merck breakthrough could usher in wave of cancer vaccines

Merck and Moderna's personalized cancer vaccine shows promise for melanoma patients. This new treatment trains the immune system to target specific tumor mutations. The vaccine, combined with Keytruda, significantly reduced cancer recurrence in trials. Doctors are hopeful this approach will expand to treat many other cancer types. Further trials are underway for lung, bladder, kidney, pancreatic, and stomach cancers.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/p51oUgc
via IFTTT

Read More

Pharma giant Cipla completes merger with wholly-owned subsidiary Inzpera Health Sciences

Pharmaceuticals giant Cipla announced its merger with Inzpera Healthsciences Limited on Wednesday. This consolidation aims for more efficient resource utilisation and greater economies of scale. The merger will improve operating parameters and maximise shareholder value through integration. Greater efficiency in cash management and access to cash flows is also expected. Business processes will be simplified, reducing administrative expenses and compliance costs.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/CBf5Zeo
via IFTTT

Read More

Lord’s Mark Industries announces license for biomescan analytics platform

Lord's Mark Industries has obtained a license for its groundbreaking Biomescan Analytics Platform, which specializes in assessing the gut microbiome to deliver customized health insights. With ambitious plans to set up 3,000 health centers across India in the next three years, the initiative aims to offer gut assessments and personalized nutritional advice, promoting proactive health and enhancing long-term wellness outcomes.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Xolc8ZJ
via IFTTT

Read More